title: Paradoxical response to tuberculosis treatment in a patient receiving tumor necrosis factor-alpha antagonist.
authors.forename: Caroline
authors.initials: C
authors.lastname: Moureau
authors.forename: Lucie
authors.initials: L
authors.lastname: Pothen
authors.forename: Dunja
authors.initials: D
authors.lastname: Wilmes
authors.forename: Jean Cyr
authors.initials: JC
authors.lastname: Yombi
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Coche
authors.forename: Philippe
authors.initials: P
authors.lastname: Hainaut
mesh_terms: D000068879:Adalimumab; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000276:immunology; D000995:Antitubercular Agents / Q000627:therapeutic use*; D018893:Bronchoalveolar Lavage; D003371:Cough / Q000382:microbiology; D004359:Drug Therapy, Combination; D005334:Fever / Q000382:microbiology; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000175:diagnosis*; D008198:Lymph Nodes / Q000382:microbiology* / Q000473:pathology; D008297:Male; D018908:Muscle Weakness / Q000382:microbiology; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification*; D009336:Necrosis; D011565:Psoriasis / Q000188:drug therapy; D014057:Tomography, X-Ray Computed; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology; D015431:Weight Loss
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000995:Antitubercular Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab